International Psoriasis Council

ADVANCING PSORIASIS RESEARCH AND TREATMENT THROUGH EDUCATION, COLLABORATION, AND INNOVATION

EDUCATION:TO ENHANCE THE CARE OF PATIENTS WORLDWIDE, IPC DELIVERS VARIOUS EDUCATIONAL PROGRAMS FOR HEALTHCARE PROFESSIONALS WORLDWIDE. THESE PROGRAMS INCLUDED: SYMPOSIUM AT MAJOR CONGRESSES, WEBINARS, MASTERCLASSES, AND THE INTERNATIONAL FELLOWSHIP PROGRAM. IPC ALSO PRODUCED ONLINE CONTENT THROUGH VIDEOS, EXPERT COMMENTARIES, AND CONGRESS REPORTS. IPC EXPERTS DISCUSSED VARIOUS TOPICS, INCLUDING IMMUNOLOGY, COMORBIDITIES, EARLY INTERVENTION, BIOMARKERS, PUSTULAR PSORIASIS, AND REAL-WORLD DATA. MORE THAN 30,000 PROFESSIONALS WERE PROVIDED WITH DISEASE INFORMATION, MEDICAL EDUCATION, AND CLINICAL RESOURCES THROUGH THESE ACTIVITIES.

OUTREACH AND OTHER PROGRAMS:CONVENING THE GLOBAL COMMUNITY OF EXPERTS: IN 2022, IPC CONVENED ITS GLOBAL NETWORK OF PSORIASIS EXPERTS TO DISCUSS CRITICAL ISSUES AFFECTING THE FIELD. THESE TOPICS INCLUDED DISEASE MODIFICATION, COMORBIDITIES, PERSONALIZED TREATMENT, DISEASE MEMORY, PATHOMECHANISM, EARLY INTERVENTION, BIOMARKERS, DIVERSITY, SKIN COLOR, AND GENETIC HETEROGENEITY.

RESEARCH:COVID-19 RESOURCE CENTER AND THE PSOPROTECT REGISTRY: THE IPC BOARD OF DIRECTORS HAS CONTINUED TO MONITOR THE PANDEMIC'S EFFECT ON PSORIASIS CARE AND, IN DECEMBER 2022, ISSUED AN UPDATED STATEMENT ON COVID-19. THE WEB-BASED COVID-19 RESOURCE CENTER HAS RECEIVED OVER 15,000 VISITS TO DATE. IT INCLUDES VIDEOS FEATURING REAL-WORLD EXPERIENCES FROM PHYSICIANS, EXPERT OPINIONS ON PUBLISHED MANUSCRIPTS, LINKS TO TREATMENT GUIDELINES, AND INFORMATION ON THE PSOPROTECT AND PSOPROTECTME COVID-19 REGISTRIES. ADDITIONALLY, A NEW COVID-19 TASK FORCE WAS LAUNCHED TO RECOMMEND ACTIVITIES IN THE FUTURE YEARS. IN 2023, IPC WILL RENAME THE COVID-19 RESOURCE CENTER TO THE INFECTIOUS DISEASE RESOURCE CENTER TO INCLUDE UPDATES ON ...(CONTINUED ON SCH O)(RESEARCH CONTINUED) ALL COMMUNICABLE DISEASES THAT AFFECT PEOPLE WITH PSORIASIS.GLOBAL BURDEN OF PEDIATRIC PSORIASIS (NEW): TO LEAD EFFORTS TO TAILOR THE MEDICAL TREATMENT OF PSORIASIS TO EACH INDIVIDUAL PATIENT, THE IPC COMMISSIONS BEST-EVIDENCE REVIEW PAPERS ANNUALLY. IN 2022, IPC DEVELOPED THE GLOBAL BURDEN OF PEDIATRIC PSORIASIS PROJECT, COMPRISED OF A SMALL GROUP OF IPC COUNCILORS AND COLLEAGUES TO WORK WITH A VETTED EDUCATIONAL INSTITUTION, THE PACIFIC NORTHWEST EVIDENCE-BASED PRACTICE CENTER AT OHSU, TO CONDUCT A SYSTEMATIC REVIEW OF EXISTING LITERATURE. PUSTULAR PSORIASIS: IPC'S PUSTULAR PSORIASIS PROJECT AIMS TO IMPROVE THE UNDERSTANDING OF THIS RARE AND LIFE-THREATENING DISEASE AND WILL INCLUDE ACTIVITIES TO IMPROVE PATIENT CARE. THE RECENTLY FORMED WORKING GROUP IS CURRENTLY DEVELOPING PRELIMINARY PLANS, WHICH MAY INCLUDE: DEFINING THE OBJECTIVES AND ADDRESSING THE FEASIBILITY OF REAL-WORLD DATA COLLECTION THROUGH INTERNATIONAL COLLABORATION WITH PUSTULAR PSORIASIS CLINICAL CENTERS AND LABORATORIES, REACHING A GLOBAL CONSENSUS ON PUSTULAR PSORIASIS SCORING ASSESSMENTS; INITIATING INTRA-RATER AND INTER-RATER VARIABILITY VALIDATION STUDIES; DEVELOPING TRAINING MODULES ON PUSTULAR SCORES AND CERTIFICATION FOR CLINICAL TRIAL INVESTIGATORS; AND HOSTING AN EXPERT ROUNDTABLE/MEETING ON PUSTULAR PSORIASIS IN ASIA.

ACCESS TO CARE:SKIN OF COLOR (NEW): THE SKIN OF COLOR (SOC) WORKING GROUP WAS DEVELOPED AND WILL WORK TO BETTER UNDERSTAND THE UNMET NEEDS AROUND PSORIASIS ON THE SKIN OF COLOR, IMPROVE THE ABILITY OF DERMATOLOGISTS TO DIAGNOSE AND TREAT PSORIASIS IN INDIVIDUALS WITH SKIN OF COLOR, AND SUPPORT AND COLLABORATE ON ACTIVITIES BY OTHER ORGANIZATIONS RELATED TO SKIN COLOR IN PSORIASIS INCLUDING PATIENT AND DERMATOLOGY ASSOCIATIONS. PRELIMINARY PLANS FOR 2023 INCLUDE: PREPARING AN UP-TO-DATE NARRATIVE LITERATURE SEARCH, CREATING AN ATLAS OF IMAGES OF SKIN OF COLOR AND PSORIASIS, CREATING EDUCATIONAL TOOLS AND RESOURCES FOR CLINICIANS, AND EXPLORING COLLABORATIONS WITH OTHER ORGANIZATIONS SUCH AS IFPA AND THE SKIN OF COLOR SOCIETY. (CONTINUED ON SCH O) (ACCESS TO CARE CONTINUED) RECLASSIFICATION OF DISEASE SEVERITY: IN 2019, IPC PUBLISHED A CONSENSUS STATEMENT THAT REJECTED THE TRADITIONAL CLASSIFICATIONS OF PSORIASIS AS MILD, MODERATE, AND SEVERE AND INSTEAD RECOMMENDED THAT PSORIASIS PATIENTS BE CLASSIFIED AS EITHER A CANDIDATE FOR TOPICAL THERAPY OR A CANDIDATE FOR SYSTEMIC THERAPY. OVER THE PAST YEAR, IPC HAS EDUCATED OVER 5,000 DERMATOLOGISTS, THROUGH MASTERCLASSES, CONGRESS SYMPOSIA, AND OUR TAKE TEN VIDEO PROJECT ON THE VALUE OF USING THE NEW CATEGORIZATION IN THEIR DAILY PRACTICE TO INCREASE THE NUMBER OF PATIENTS RECEIVING THE APPROPRIATE TREATMENT. IN ADDITION, IPC WORKED WITH NATIONAL ENTITIES TO SECURE THE INCLUSION OF THE CLASSIFICATION IN THE UPDATE OF TWO EUROPEAN TREATMENT GUIDELINES AND PARTNERED WITH THE NPF TO ANALYZE THEIR ANNUAL PATIENT SURVEY DATE. THE ANALYSIS IS COMPLETE, AND A MANUSCRIPT IS CURRENTLY IN DEVELOPMENT. TELEMEDICINE: THE TELEMEDICINE WORKING GROUP WAS CREATED TO ESTABLISH A ROAD MAP FOR HOW IPC CAN AID THE DEVELOPMENT AND IMPLEMENTATION OF TELEMEDICINE FOCUSED ON PSORIASIS DIAGNOSIS AND MANAGEMENT. CONSIDERING CULTURAL AND TECHNOLOGICAL DIFFERENCES, THE TELEMEDICINE WORKING GROUP HAS COMPLETED A GLOBAL CONSENSUS STATEMENT REGARDING TELEMEDICINE IN PSORIASIS MANAGEMENT. THE PUBLICATION "TELEMEDICINE AND PSORIASIS: A REVIEW BASED ON STATEMENTS OF THE TELEMEDICINE WORKING GROUP OF THE INTERNATIONAL PSORIASIS COUNCIL" IS NOW AVAILABLE ON THE IPC'S WEBSITE. ADDITIONAL ACTIVITIES WILL INCLUDE DEFINING BEST PRACTICES FOR USING TELEMEDICINE IN TREATING PSORIASIS, EDUCATING DERMATOLOGISTS ON BOTH THE OPPORTUNITIES AND LIMITATIONS OF TELEMEDICINE, AND RESEARCH TO UNDERSTAND BETTER THE BARRIERS TO CARE BASED ON CURRENT REIMBURSEMENT POLICIES ON A GLOBAL LEVEL.GLOBAL PSORIASIS ATLAS (GPA): PHASE TWO OF THE GLOBAL PSORIASIS ATLAS (GPA) PROJECT HAS BEEN INITIATED IN PARTNERSHIP WITH THE ILDS (INTERNATIONAL LEAGUE OF DERMATOLOGICAL SOCIETIES) AND IFPA (INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS). THE UNIVERSITY OF MANCHESTER CONTINUES TO SERVE AS THE LEAD ACADEMIC INSTITUTION FOR THE PROJECT. WORKSTREAMS FOR PHASE TWO INCLUDE: -EPIDEMIOLOGY OF PSORIASIS, -EARLY DIAGNOSIS OF PSORIASIS, -COMORBID DISEASE BURDEN OF PSORIASIS, AND -THE ECONOMIC IMPACT OF PSORIASIS.DURING 2022, FOUR MANUSCRIPTS WERE PUBLISHED ON TOPICS INCLUDING PREVALENCE, COMORBIDITIES, AND MORTALITY OF GENERALIZED PUSTULAR PSORIASIS; THE INCIDENCE, PREVALENCE, AND MORTALITY OF PSORIASIS IN TAIWAN AND MALAYSIA; AND MAPPING OPPORTUNITIES FOR THE EARLIER DIAGNOSIS OF PSORIASIS IN PRIMARY CARE SETTINGS IN THE UNITED KINGDOM. FURTHERMORE, A CLINICAL DIAGNOSTIC TRAINING TOOL HAS BEEN DEVELOPED AND PILOTED WITH GENERAL PRACTITIONERS, NURSES, AND PHARMACISTS.